In these studies very high doses (up to 4800 CCA units in adults) of formalin inactivated influenza vaccine purified by density gradient centrifugation were given safely to more than 5000 volunteers drawn from adolescent, middle aged and elderly populations. The relative paucity of reactions, compared with those groups receiving much lower doses of formalin-inactivated vaccine produced by Sharples centrifugation, suggests that reactions are due to non-viral substances rather than to toxic properties of the viruses, and that these substances are removable.
Summary
In these studies very high doses (up to 4800 CCA units in adults) of formalin inactivated influenza vaccine purified by density gradient centrifugation were given safely to more than 5000 volunteers drawn from adolescent, middle aged and elderly populations. The relative paucity of reactions, compared with those groups receiving much lower doses of formalin-inactivated vaccine produced by Sharples centrifugation, suggests that reactions are due to non-viral substances rather than to toxic properties of the viruses, and that these substances are removable.
Homologous serum HI antibody responses increased with increasing vaccine dosage and there was no plateau effect at the higher dose level. In those groups studied, the appearance of neutralizing activity in post-vaccination nasal washings correlated closely with the higher vaccine doses and higher HI antibody titres.
The occurrence of the 'Hong Kong flu' epidemic in two of the groups, including over 3000 vaccine recipients, provided a unique opportunity to study the efficacy of the various vaccines used. Only those groups receiving high doses of a Hong Kong-like antigen (A2/Aichi/2/68) enjoyed significant reduction reduction in the incidence of fever in that group.
These results indicate that very large doses of purified influenza vaccine can be given safely. Significant prevention and modification of disease caused by influenza via the vaccine approach is dependent on the administration of large doses of the appropriate antigen.
IN a previous study (Kaye, Dowdle & McQueen, 1969) we demonstrated in mice that protection against a broad spectrum of heterotypic influenza A (Asian) strains could be achieved with increasing concentrations of aqueous inactivated influenza vaccine. These results suggested that more concentrated doses of vaccine might also broaden the antibody response and provide better protection in man. Although the dose-related frequency of local and systemic reactions precluded the use of high concentrations of conventional Sharples centrifuged vaccines, initial reports of low toxicity of vaccine prepared by zonal ultracentrifugation were encouraging (Reimer et al., 1967; Peck, 1968 ).
Here we review some of our findings with volunteers inoculated with high doses of vaccine purified by zonal ultracentrifugation. For convenience the review is presented in two parts: first, the 1967-68 studies of increasing dosage of vaccine and its effect in terms of adverse reaction and antibody response in volunteers and, second, the 1968-69 studies of the efficacy of high doses of vaccine in preventing natural disease in man. Both of these studies are described in detail elsewhere Schoenbaum et al., 1969; Mostow et al., 1970) .
The effect of increasing dosage of influenza vaccine in terms of reactions and antibody responses in volunteers Methodology
In this study, purified A/Japan/305/57 (H2N2) influenza vaccines were given subcutaneously in graded doses of 300-4800 CCA units. Standard Sharples vaccines at 300 and 600 CCA units were employed as well as a control vaccine containing all components of zonal vaccine except the virus. The vaccines, method of production and dosage in CCA units are listed in Table 1 . Vaccines were administered in 1 ml amounts by jet injector gun to volunteers from the Atlanta Federal Penitentiary. Because the adverse effects of very large doses of purified vaccines were not known, each dose increment was given on alternate days so that recipients could be observed for 48 hr before the group receiving the next higher dose was vaccinated.
Serum and nasal specimens were collected before and 3 weeks after vaccination. Serum specimens were examined by haemagglutination inhibition (HI) tests, and nasal washings were examined by conventional virus neutralization tests (Robinson & Dowdle, 1969 group.bmj.com on July 2, 2017 -Published by http://pmj.bmj.com/ Downloaded from increased with dosage as did the titres to a wide variety of antigens isolated up to 10 years after the vaccine strain. No plateau effect was observed, and titres of 5120, 10,240 and even 20,480 were not uncommon. The effects of increasing dosages of vaccine are more dramatically illustrated if we look at fold increase in geometric mean HI titre. The 300 CCA unit vaccine produced a seven-fold increase in homologous geometric mean HI titre, whereas the 4800 CCA unit vaccine produced a thirty-five-fold increase (Fig. 1) .
The presence of neutralizing substances in nasal washings after subcutaneous immunization also increased with vaccine dose (Fig. 2) . The 300 CCA unit vaccine resulted in nasal-wash neutralizing activity in 40%o of the recipients, whereas the 4800 CCA unit vaccine resulted in neutralizing activity in 80%/.
These results indicated that high doses of inactivated influenza vaccines prepared by zonal ultracentrifugation could be given safely to adults with essentially no greater adverse reaction rate than has been associated with standard doses of Sharples vaccines. Although the serum and nasal secretory antibody responses to the higher doses suggested that increased protection might be conferred upon the recipients, efficacy of the higher doses for prevention of natural infection remained to be proven. The efficacy of high doses of influenza vaccines, purified by zonal ultracentrifugation in preventing natural disease in man Methodology
In this study purified A/Japan/170/62 (H2N2), A/Aichi/2/68 (H3N2), and B/Mass/3/66 vaccines at 300 and 3000 CCA units each were evaluated for adverse reactions and antibody responses in populations in three locations: the Georgia State Prison, secondary schools in California, and a retirement community in California. In addition, each of the vaccines was evaluated for effectiveness in prevention of illness caused by Hong Kong influenza in the Georgia State Prison and retirement community populations.
The methods of vaccine administration, collection and testing of specimens were similar to those described for previous trials .
Reactions to the vaccines were also evaluated at the Georgia State Prison as described for the previous study. At the retirement community and schools, each vaccinee was given a questionnaire concerning the systemic and local reactions listed for the prisoners and was requested to complete and return it 4 days after vaccination. In addition, school absenteeism was tabulated for vaccinated and unvaccinated students for the 3 days immediately following injections.
Adverse reactions
In the Georgia State Prison local reactions to high doses of all the zonal purified vaccines were greater than those to the lower doses but, in general, were less severe than those associated with the Sharples vaccines (Table 3) . Systemic reactions, including fever, were also relatively infrequent except for those receiving the 3000 CCA unit B/Mass/3/66 vaccine.
In the retirement community, two-thirds of those persons receiving a low dose of zonally purified vaccine reported no symptoms (Table 4) , and nearly half of the high dose recipients had no reaction. In contrast, more than two-thirds of the recipients of the standard dose of Sharples vaccine had either a local or systemic reaction, or both.
Students recorded adverse reactions to the A vaccines twice as frequently as the adults at the retirement community (Table 5) Recipients of A/Japan and B/Mass vaccines had fewer homologous four-fold rises than the Aichi vaccines. This probably reflects previous exposure to strains similar to A/Japan and B/Mass, either through natural infection or vaccination. Prevaccination titres to the A/Japan antigen were high (Table 6b) , whereas prevaccination titres to the Aichi antigen were low (< 10 GMT), reflecting the lack of exposure to this virus in the past. As in the Atlanta Federal Penitentiary study the year before, the higher doses of Avaccines stimulated large increases in GMT.
Vaccine efficacy
In late December 1968, the physician-in-charge reported a sharp increase in febrile respiratory disease at the Georgia State Prison. The Hong Kong variant was isolated from the throat swabs of thirty of forty-two prisoners seen at sick call. All forty-two had diagnostic serologic rises to the Hong Kong antigen. In addition, 74°/ of those who said they had an influenza-like illness on interview demonstrated four-fold or greater rises in antibody to the Hong Kong virus. Details of surveillance procedures and methods of assessing efficacy have been previously reported .
Comparison of the attack rates in the groups which received different vaccines revealed the following (Table 7) :
(1) The attack rate among inmates receiving 300 CCA units of B/Mass vaccine were similar to those among men receiving the 300 CCA unit A/Japan vaccine. These similarities also were seen among the 3000 CCA unit recipients of the same vaccines.
(2) Based upon the criteria of history of a febrile illness, going to bed, or attendance at sick call, the attack rates for the 3000 CCA unit B/Mass or A/Japan vaccine were lower than for recipients of the 300 CCA unit dose of these vaccines, but these differences were not statistically significant (P> 0-05). The epidemic at the retirement community, an open population, should better reflect the performance of the vaccine in a natural epidemic. Using the attack rates among the recipients of the 300 CCA units of A/Japan vaccine as a baseline, we observed the following (Table 8): (1) The attack rates of 300 and 3000 CCA unit A/Japan/170/62 vaccine recipients were essentially the same.
(2) The recipients of the commercial polyvalent vaccine again showed the highest attack rates.
(3) The reduction of illness by the 300 CCA unit A/Aichi vaccine was not statistically significant (P> 0-05) .
(4) The nearly 6000 reduction in attack rate by the 3000 CCA unit A/Aichi vaccine was significant (P < 05).
(5) The 3000 CCA unit A/Aichi vaccine recipients who were ill experienced less severe illness than those in the other vaccine groups.
Discussion
In this series of human volunteer trials, we have demonstrated that unusually high doses of influenza vaccine purified by zonal centrifugation can be given safely to both adults and older children. Although the students in the 1968 trials reported reactions twice as frequently as adults, class attendance was not affected except among those receiving the high dose of B/Mass/3/66 vaccine. The reactions associated with this vaccine may have been in some way related to the manufacture of this single vaccine lot. However, the possibility that B/Mass vaccine might be inherently more toxic than A vaccines cannot be ruled out. New criteria for safety and purity may be possible now that vaccines of increased concentration and purity are available. The removal of nonviral material through zonal centrifugation did not detract from the antibody response, suggesting that a local reaction is not necessary for an adjuvant effect. Stepwise increases in vaccine concentration produced stepwise increases in serum antibody. The higher concentrations of vaccine in the 1967-68 study also stimulated the appearance of neutralizing substances in the nasal secretions. In the 1968-69 trials, we were able to demonstrate a protective effect of the high (3000 CCA unit) Aichi vaccine against illness caused by the Hong Kong virus. Calculations of vaccine efficacy were remarkably similar for the two populations separated by 2000 miles. Using both the B/Mass and A/Japan groups as a baseline, we determined that the protective efficacy of the 3000 CCA unit Aichi vaccine was 60-70%. No significant protection was afforded bythe standard vaccine dose. Of those persons in both populations who received the high dose of Aichi vaccine, relatively fewer had to be confined to bed or consult a physician. Among those who had fever, relatively fewer had high fevers. Thus, the high-dose vaccine was associated with less severe illness and with a reduction in confinement to bed.
We have demonstrated that increased dosages of highly purified vaccines can be given safely to adults and older children and that these dosages provide substantially better protection against illness than the previously recommended standard dose. 
